文献速递造血干细胞移植与细胞治疗白血病淋巴瘤

CAR-T细胞治疗后急性脊髓病的临床特征、病理生理与管理

Clinical features, pathophysiology, and management of acute myelopathy following CAR T-cell therapy.
PubMed 文献 · Blood · 2024-01-01

嵌合抗原受体(CAR)T细胞疗法革新了复发或难治性血液肿瘤的治疗,但伴随细胞因子释放综合征和ICANS等独特毒性。随着经验积累,急性脊髓病等少见神经并发症报道增多,而现有ICANS共识指南对该罕见并发症的检查和治疗指导有限。本文探讨CAR-T治疗后急性脊髓炎的临床特征、病理生理和优化管理策略,并从文献报道病例中汲取经验。

要点

  • CAR-T治疗后急性脊髓病报道逐渐增多,属少见神经并发症。
  • 现有ICANS共识指南对该罕见并发症的检查和治疗指导有限。
  • 本文聚焦临床特征、病理生理与优化管理策略。

核心结论

  • CAR-T治疗后急性脊髓病报道增多,现有ICANS共识指南对该罕见并发症的检查和治疗指导有限。

研究设计与样本

  • 本文为综述,检索范围未在原文明确报告。

主要发现

  • CAR-T疗法伴随细胞因子释放综合征和ICANS等独特毒性。
  • 随着CAR-T经验积累,急性脊髓病等少见神经并发症报道逐渐增多。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 现有ICANS共识指南对该罕见并发症的适当检查和治疗指导有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of patients with relapsed or refractory hematologic malignancies, but it comes with unique toxicities, notably cytokine release syndrome and ICANS (immune effector cell-associated neurotoxicity syndrome). As experience with CAR T-cell therapy grows, distinct and infrequent neurologic complications are becoming increasingly evident. Recently, reports of acute myelopathy after the administration of CAR T-cell therapies have been accumulating. Despite the establishment of consensus guidelines for managing ICANS, there remains limited guidance on the appropriate investigations and treatments for this rare complication. In this manuscript, we delve into the clinical features, pathophysiology, and strategies for the optimal management of acute myelitis after CAR T-cell therapy and draw insights from reported cases in the literature.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Deschênes-Simard X, Santomasso BD, Dahi PB, et al. Clinical features, pathophysiology, and management of acute myelopathy following CAR T-cell therapy. Blood. 2024. PMID: 39226460. doi:10.1182/blood.2024025679

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。